全文获取类型
收费全文 | 1211篇 |
免费 | 61篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 83篇 |
妇产科学 | 18篇 |
基础医学 | 130篇 |
口腔科学 | 23篇 |
临床医学 | 86篇 |
内科学 | 278篇 |
皮肤病学 | 31篇 |
神经病学 | 62篇 |
特种医学 | 84篇 |
外科学 | 122篇 |
综合类 | 30篇 |
一般理论 | 2篇 |
预防医学 | 29篇 |
眼科学 | 40篇 |
药学 | 101篇 |
中国医学 | 2篇 |
肿瘤学 | 132篇 |
出版年
2023年 | 5篇 |
2022年 | 16篇 |
2021年 | 41篇 |
2020年 | 9篇 |
2019年 | 28篇 |
2018年 | 24篇 |
2017年 | 17篇 |
2016年 | 29篇 |
2015年 | 23篇 |
2014年 | 39篇 |
2013年 | 60篇 |
2012年 | 75篇 |
2011年 | 73篇 |
2010年 | 30篇 |
2009年 | 32篇 |
2008年 | 59篇 |
2007年 | 56篇 |
2006年 | 63篇 |
2005年 | 67篇 |
2004年 | 77篇 |
2003年 | 56篇 |
2002年 | 53篇 |
2001年 | 29篇 |
2000年 | 24篇 |
1999年 | 26篇 |
1998年 | 8篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1992年 | 16篇 |
1991年 | 19篇 |
1990年 | 14篇 |
1989年 | 16篇 |
1988年 | 12篇 |
1987年 | 18篇 |
1986年 | 18篇 |
1985年 | 13篇 |
1984年 | 8篇 |
1983年 | 12篇 |
1982年 | 6篇 |
1980年 | 6篇 |
1979年 | 11篇 |
1978年 | 11篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1975年 | 6篇 |
1974年 | 7篇 |
1973年 | 4篇 |
1972年 | 6篇 |
1970年 | 6篇 |
1969年 | 6篇 |
排序方式: 共有1273条查询结果,搜索用时 46 毫秒
81.
Handa KK Bhalla AP Arora A 《International journal of pediatric otorhinolaryngology》2001,60(3):109-242
Fire during the use of Nd–Yag laser is a very rare complication. A case report of laser fire during the use of Nd–Yag laser for congenital subglottic stenosis is reported. The probable causes for the fire, management and short review of literature are dealt with. This case report highlights the importance of following the safety protocol during laser surgery. 相似文献
82.
HL-60/Bcr-Abl cells, with ectopic expression of p185 Bcr-Abl tyrosine kinase (TK), and K562 cells, with endogenous expression of p210 Bcr-Abl TK, display a high degree of resistance against antileukemic drug-induced apoptosis (G. Fang et al., Blood, 96: 2246-2256, 2000). Present studies demonstrate that treatment with ansamycin antibiotic geldanamycin (GA), or its less toxic analogue 17-allylamino-17-demethoxygeldanamycin (17-AAG), induces cytosolic accumulation of cytochrome c and cleavage and activities of caspase-9 and caspase-3, triggering apoptosis of HL-60/Bcr-Abl and K562 cells. GA or 17-AAG down-regulated intracellular Bcr-Abl and c-Raf protein levels, as well as reduced Akt kinase activity. Similar to Raf-1, v-Src, and Her-2-neu, Bcr-Abl TK has chaperone association with heat shock protein 90 (Hsp90). By binding and inhibiting Hsp90, GA or 17-AAG treatment shifted the binding of Bcr-Abl from Hsp90 to Hsp70 and induced the proteasomal degradation of Bcr-Abl, because cotreatment with proteasome inhibitor PSC341 reduced both GA (or 17-AAG)-mediated down-regulation of Bcr-Abl levels and inhibited apoptosis of HL-60/Bcr-Abl and K562 cells. These data establish the in vitro activity of GA and 17-AAG against Bcr-Abl-positive leukemic cells and support the in vivo investigation of 17-AAG against Bcr-Abl-positive leukemias. 相似文献
83.
Ogbogu P Fleischer AB Brodell RT Bhalla G Draelos ZD Feldman SR 《Archives of dermatology》2001,137(2):151-154
OBJECTIVE: To describe physicians' and patients' reasons for participating in office-based sales of dermatologic products. DESIGN: Survey data on the attitudes, opinions, and beliefs of dermatologists and their patients were analyzed. SETTING: A market research study of office-based selling. PARTICIPANTS: Thirty dermatologists involved in direct selling from the office, 20 dermatologists not involved in direct selling, 22 patients who purchase products from their dermatologists' offices, and 25 office managers. MAIN OUTCOME MEASURE: The hypotheses of this study were formulated after the market research study had been done. The main outcome measure was the physicians' and patients' reported reasons for patients purchasing skin care products from dermatologists rather than from retail stores. RESULTS: "Trust" was the most frequent reason cited by physicians for patient purchases, while "physician knowledge" was the most frequent reason cited by the purchasing patients. The most common location to display the products was the waiting room (20 [67%] of the physicians). The most common types of products sold included glycolic acid products (15 [50%]), moisturizers (13 [43%]), sunscreens (12 [40%]), and alpha-hydroxy acid products other than glycolic acid (9 [30%]). CONCLUSION: The interaction between physicians who sell products in their offices and their patients is highlighted by 2 key elements of the physician-patient relationship: trust and physician knowledge. 相似文献
84.
85.
K N Bhalla G N Kumar U K Walle A M Ibrado T Javed R K Stuart C Reed S G Arbuck T Walle 《Clinical cancer research》1999,5(7):1723-1730
A Phase I and pharmacological study of paclitaxel administered as an outpatient, 3-h i.v. infusion just before a 5-day regimen of daily cisplatinum (CP) and a continuous infusion of 5-fluorouracil (5-FU) was performed in patients with advanced solid tumors. A secondary objective was to determine the objective response rate to this regimen. Forty-two patients were enrolled and were evaluable for toxicities. Eighteen patients were previously untreated, whereas the rest had received prior treatment with radiation (J. H. Schiller et al., J. Clin. Oncol., 12: 241-248, 1994), chemotherapy (M. J. Kennedy et al., Clin. Cancer Res., 4: 349-356, 1998), or both modalities (J. H. Schiller et al., J. Clin. Oncol., 12: 241-248, 1994). The paclitaxel dose was escalated from 100-135-170-200-225 to 250 mg/m2, whereas i.v. 5-FU and CP doses were fixed at 1.0 g/m2/day continuous infusion and 20 mg/m2/day, respectively, daily for 5 days. Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg/day) was administered s.c. from day 6, routinely after 250 mg/m2 dose of paclitaxel or after a lower dose of paclitaxel if ANC <500/microl or febrile neutropenia was observed. Patients were treated every 28 days. Plasma and urine samples were collected to determine the pharmacokinetics of paclitaxel. In previously untreated patients, the maximally tolerated dose of paclitaxel in the drug regimen was determined to be 170 mg/m2 without and 250 mg/m2 with G-CSF support. At the higher dose level, mucositis and thrombocytopenia were dose-limiting. In previously treated patients, these toxicities were observed at all dose levels of paclitaxel > or =135 mg/m2. With increasing doses of paclitaxel, a disproportionate increase in the peak concentrations, as well as the area under plasma concentration time-curve, was seen. This nonlinearity was due to saturable total body clearance and volume of distribution of paclitaxel (P < 0.001). The apparent plasma elimination half-life was unaffected by the dose of paclitaxel. CP and 5-FU had no apparent effect on the metabolism of paclitaxel. Among 32 patients evaluable for response, 22 demonstrated an objective response, including five complete remissions. Therefore, a regimen of 3-h infusion of 250 mg/m2 paclitaxel before CP and FU is tolerable with G-CSF (as above) support in previously untreated patients. The regimen also seems to be highly active against breast and esophageal cancers. 相似文献
86.
A study of twins 总被引:1,自引:0,他引:1
87.
88.
89.
90.